Tirzepatide in Houston, with the real clinical process that makes results stick.
Get the lasting weight loss you've been working toward — through the real clinical process that makes results stick. A once-weekly injection, also known as Mounjaro or Zepbound.
A once-weekly injection for sustained, clinically meaningful weight loss.
Tirzepatide is a dual-incretin agonist — it activates both GLP-1 and GIP receptors, the two hormone pathways your body uses to regulate appetite, blood sugar, and nutrient processing. The dual mechanism is why tirzepatide consistently produces greater weight loss in head-to-head trials than semaglutide alone.
FDA-approved as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Available as both branded FDA-approved formulations and, where appropriate, as compounded preparations from licensed 503A and 503B pharmacies. We discuss the regulatory and quality differences during consultation so you understand exactly what you’re being prescribed and why.
Tirzepatide is one tool — and a powerful one — but the patients who keep the weight off are the ones who treat the medication as part of a real metabolic conversation that includes sleep, stress, training, and protein. The medication makes the work easier; it doesn’t replace the work.
The case for tirzepatide, honestly.
Tirzepatide isn’t always the right first answer. But for patients with significant weight to lose, established metabolic dysfunction, or insufficient response to semaglutide, it’s the strongest tool we currently prescribe. Here’s how we think about it.
Dual incretin action
Activates both GLP-1 and GIP receptors. The GIP component appears to amplify the GLP-1 effect on appetite, satiety, and glucose handling — which is why tirzepatide tends to outperform semaglutide in direct comparison.
Evidence: Strong · SURMOUNT-1 + SURPASS trialsLarger weight loss in trials
SURMOUNT-1 showed mean reductions of ~16%, ~21.4%, and ~22.5% at 5mg, 10mg, and 15mg doses over 72 weeks. For comparison, semaglutide STEP-1 trials averaged ~14.9%. Real-world response varies; trial averages aren’t promises.
Evidence: Strong · Direct head-to-head data emergingSide-effect profile is workable
GI side effects (nausea, constipation, fullness) are real but generally manageable with slow dose titration. Most patients tolerate the medication well after the first 2–4 weeks. We adjust dose timing and titration speed individually.
Evidence: Strong · Consistent across trials and clinical useTirzepatide vs Semaglutide.
The two leading GLP-1-class medications in 2026. They share mechanisms, but the differences are clinically meaningful — and the right choice depends on your specific situation.
Semaglutide
Ozempic · Wegovy · Rybelsus
Single-receptor agonist (GLP-1). Longest track record. Approved 2017 (Ozempic) and 2021 (Wegovy for weight loss).
- Strongest evidence base across cardiovascular and metabolic endpoints
- Often the first-line choice when starting GLP-1 therapy
- Generally well-tolerated; GI side effects common during titration
- Manufacturer savings programs often more accessible
Tirzepatide
Mounjaro · Zepbound
Dual-receptor agonist (GIP + GLP-1). Approved 2022 for diabetes; 2023 for weight management; 2026 for sleep apnea in obesity.
- Greatest absolute weight loss in head-to-head SURMOUNT trials
- Often more effective for patients who plateaued on semaglutide
- Some patients tolerate it better; others find it harder
- Newer indications expanding (sleep apnea in obesity, others under review)
Tirzepatide is a tool. Foundations are the work.
Clinical trial data is impressive. Real-world long-term outcomes depend heavily on what you build alongside the medication — sleep, training, nutrition, and stress management. We treat that work as part of the program, not as fine print.
The medication makes the work possible. It doesn’t replace it.
Tirzepatide reduces the biological pull toward overeating — for many patients, dramatically. That creates an opening. What fills that opening determines whether the results last beyond the prescription.
- Adequate protein intake to preserve lean mass during weight loss
- Daily movement — walking counts, and consistency beats intensity
- Sleep, stress, and alcohol — the three biggest hidden derailers
- An exit plan from day one, whether you taper or stay on therapy long-term — discussed openly during our metabolic reset program
From consultation to first injection, in real medicine.
Tirzepatide prescribing follows the same clinical pattern as any other thoughtful prescribing decision — proper workup first, then a decision based on what your labs and history actually show.
Initial consultation
In person at our Houston clinic. We discuss your full medical history, what you’ve tried, current weight and metabolic picture, and whether tirzepatide is the right fit. No prescription written this day.
Comprehensive lab work
A full metabolic workup at LabCorp or Quest near you — A1c, fasting insulin, lipid panel, comprehensive metabolic panel, thyroid (TSH, free T4), inflammatory markers, and any indication-specific testing. Pancreatic and thyroid contraindication screening included.
Protocol design
Your physician designs your specific protocol — starting at 2.5mg weekly with a measured titration schedule, route (subcutaneous, weekly), and monitoring cadence. We discuss expected timeline, side effects, and how we’ll respond if titration needs to slow.
First injection
FDA-approved or compounded medication delivered with detailed dosing instructions. We provide injection training (subcutaneous, well-tolerated by most), side-effect guidance, and clear expectations: noticeable appetite changes typically begin within the first 1–2 weeks, with weight changes following at 4–8 weeks.
Monitor & adjust
Structured check-ins at 4, 12, and 24 weeks. Lab repeat at 12 and 24 weeks. We adjust dose based on actual response and tolerability — not on a fixed escalation schedule. After the initial treatment phase, we discuss the transition into ongoing metabolic care.
Ready to start the conversation?
A 45-minute consultation with one of our physicians. We’ll review your specific situation and decide together whether tirzepatide fits — or whether something else makes more sense for what you’re working on.
What tirzepatide can — and can’t — do.
The evidence for tirzepatide in significant weight loss is strong. The gap between what well-prescribed tirzepatide delivers and what the internet promises is still enormous. Here’s what to realistically expect.
What tirzepatide does well
- Produces meaningful, sustained weight loss for most patients (mean ~15–22% over 72 weeks)
- Improves A1c, fasting glucose, and insulin sensitivity in most metabolically dysfunctional patients
- Reduces visceral fat preferentially, with measurable improvements in body composition
- Decreases blood pressure and triglycerides as collateral benefits
- Reduces self-reported food noise and compulsive eating in many patients
- Has cardiovascular safety data accumulating from SURPASS-CVOT and related trials
What it can’t do
- Replace strength training, sleep, protein, or stress management
- Be appropriate for patients with personal or family history of medullary thyroid carcinoma or MEN2
- Be a fit for patients with severe gastroparesis, active pancreatitis, or pregnancy
- Continue indefinitely without periodic reassessment of benefit, side effects, and goals
- Prevent regain if discontinued without a plan for ongoing metabolic care
- Be appropriately prescribed without baseline labs and a real clinical workup
Before you book.
How much does tirzepatide cost in Houston?
The initial consultation is $349. The medication itself varies significantly based on whether you’re on FDA-approved (Mounjaro/Zepbound) or compounded preparations, and whether your insurance covers it. Branded retail typically runs $1,000+ per month without coverage; compounded options are typically $300–$600 per month. Our ongoing program fees cover physician oversight, scheduled lab repeats, and dose adjustments — separate from medication costs. We discuss specifics during consultation, with no surprises.
What’s the difference between branded and compounded tirzepatide?
Branded tirzepatide (Mounjaro, Zepbound) is FDA-approved with extensive trial and post-market data. Compounded tirzepatide is prepared by licensed compounding pharmacies (503A or 503B) under specific regulatory frameworks, often during periods when branded supply is constrained. Quality varies significantly by pharmacy. We work only with licensed compounding partners that meet documented quality standards, and we discuss the tradeoffs honestly during consultation. Read more about FDA-approved vs. compounded medications.
How is tirzepatide different from semaglutide?
Both medications activate GLP-1 receptors. Tirzepatide additionally activates GIP receptors, which is why it tends to produce greater weight loss in head-to-head trials. SURMOUNT-1 (tirzepatide) showed mean reductions ~15–22% at varying doses over 72 weeks; STEP-1 (semaglutide) averaged ~14.9%. For some patients, semaglutide is the right starting point. For others, particularly those with significant weight to lose or established metabolic dysfunction, tirzepatide is the stronger tool. We help you decide which fits your specific picture.
What side effects should I expect?
The most common are GI: nausea, constipation, bloating, fullness, and occasional reflux. Most are mild to moderate and improve with slow dose titration. We start at the lowest effective dose (2.5mg weekly) and escalate only when tolerated. Less common but more serious effects include pancreatitis and gallbladder issues — which is why baseline labs and ongoing monitoring matter. We discuss all of this during consultation.
Will I gain the weight back when I stop?
Without a plan, yes — most patients regain a meaningful percentage of weight loss after discontinuing GLP-1 medications. This is the central question that determines whether tirzepatide is worth starting in the first place. Our approach: treat the medication as one phase of a longer metabolic conversation. We discuss what comes after — whether that’s a maintenance dose, transition to other medications, or our metabolic reset program — before you start, not after.
How long does it take to see results?
Most patients notice appetite changes within the first 1–2 weeks. Measurable weight loss typically begins at week 4–6 and accelerates through the first 16–20 weeks. Trial-equivalent results (15%+ reduction) generally require 60+ weeks of consistent therapy with appropriate dose titration. We’re honest about timelines and willing to adjust if response isn’t materializing as expected.
Do you accept insurance?
FDA-approved tirzepatide is sometimes covered for weight management or type 2 diabetes, depending on your specific plan. We provide documentation suitable for insurance submission but don’t bill insurers directly. Compounded tirzepatide is not covered by insurance. Some patients use HSA/FSA funds for consultations and ongoing program fees. Read about what to expect in your first 90 days on a GLP-1 for the broader expectations picture.
Start with a conversation, not a prescription.
A 45-minute consultation with one of our Houston physicians. We’ll review your situation, decide together whether tirzepatide fits, and what comes next.